Scilex Holding Company (SCLX)
- Previous Close
0.7454 - Open
0.7650 - Bid 0.7773 x 100
- Ask 0.8395 x 100
- Day's Range
0.7650 - 0.8388 - 52 Week Range
0.7320 - 8.3700 - Volume
500,291 - Avg. Volume
1,039,140 - Market Cap (intraday)
97.49M - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
www.scilexholding.com105
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SCLX
Performance Overview: SCLX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCLX
Valuation Measures
Market Cap
90.28M
Enterprise Value
214.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.08
Price/Book (mrq)
--
Enterprise Value/Revenue
6.16
Enterprise Value/EBITDA
-2.64
Financial Highlights
Profitability and Income Statement
Profit Margin
-244.60%
Return on Assets (ttm)
-70.16%
Return on Equity (ttm)
--
Revenue (ttm)
46.74M
Net Income Avi to Common (ttm)
-166.98M
Diluted EPS (ttm)
-1.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
3.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
33.57M
Research Analysis: SCLX
Company Insights: SCLX
SCLX does not have Company Insights